Sun Buys Ranbaxy
- All
- News
-
Continue To Remain Opportunistic For Acquisitions: Sun Pharma
Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management.
-
CCI Okays PVR-DT Cinemas Deal, Asks To Exclude Certain Assets
Competition Commission has approved multiplex chain PVR's proposed acquisition of DT Cinemas from DLF while directing the companies to exclude certain assets from the deal to address anti-competitive concerns.
-
Strides Arcolab Surges 5% on Sun Pharmaceutical Industries Deal
Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.
-
NSE Sees Record High at Rs 41,165 Cr in Cash Market Segment
Daiichi which had forayed into the Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, today sold over 21 crore shares in Sun Pharma.
-
Sun Pharma Wins US Nod to Buy Ranbaxy
Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it will sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.
-
Sun Pharmaceutical Wins US Approval to Buy Ranbaxy
India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.
-
Sun Pharma-Ranbaxy Deal Cleared by Fair Trade Regulator
The Competition Commission of India (CCI) on Monday said it has approved generic drug maker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.
-
Sensex Turns Choppy; Banks Fall
Defensives like IT and FMCG were also down by 0.27 per cent and 0.65 per cent respectively. However the pharma sub-index of NSE was up nearly half a per cent due to buying in selective counters like Ranbaxy and Sun Pharma. Ranbaxy was up 1.69 per cent at Rs 568.35 whereas Sun Pharma traded 1.06 per cent higher at Rs 769.75.
-
Sell Sun Pharma, Ranbaxy; buy Axis Bank today: Sanjeev Bhasin
For today, long in select auto, banks & infra could make money, while weakness in pharma & steel stocks should do well on the short side.
-
Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover
Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.
-
Ranbaxy's journey as a company to end after merger with Sun Pharma
Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.
-
Sebi to ask stock exchanges for trading data in Ranbaxy shares
Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.
-
Probe Ranbaxy trades ahead of Sun Pharma deal: brokers
Ranbaxy shares surged 24 per cent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy Ranbaxy for $3.2 billion.
-
Sun Pharma soars 8% on upgrades after Ranbaxy deal
Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.
-
Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats
Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co, and got Ranbaxy India-made drugs barred from the United States.
-
Continue To Remain Opportunistic For Acquisitions: Sun Pharma
Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management.
-
CCI Okays PVR-DT Cinemas Deal, Asks To Exclude Certain Assets
Competition Commission has approved multiplex chain PVR's proposed acquisition of DT Cinemas from DLF while directing the companies to exclude certain assets from the deal to address anti-competitive concerns.
-
Strides Arcolab Surges 5% on Sun Pharmaceutical Industries Deal
Shares of Strides Arcolab surged nearly 4 per cent to Rs 1,191 at its day's high after the Bangalore-based pharma company reached a deal with Sun Pharmaceutical Industries Ltd to buy two marketing divisions of erstwhile Ranbaxy Laboratories.
-
NSE Sees Record High at Rs 41,165 Cr in Cash Market Segment
Daiichi which had forayed into the Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, today sold over 21 crore shares in Sun Pharma.
-
Sun Pharma Wins US Nod to Buy Ranbaxy
Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it will sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.
-
Sun Pharmaceutical Wins US Approval to Buy Ranbaxy
India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.
-
Sun Pharma-Ranbaxy Deal Cleared by Fair Trade Regulator
The Competition Commission of India (CCI) on Monday said it has approved generic drug maker Sun Pharmaceutical Industries Ltd's $3.2 billion bid to buy smaller rival Ranbaxy Laboratories Ltd, subject to the companies divesting seven products.
-
Sensex Turns Choppy; Banks Fall
Defensives like IT and FMCG were also down by 0.27 per cent and 0.65 per cent respectively. However the pharma sub-index of NSE was up nearly half a per cent due to buying in selective counters like Ranbaxy and Sun Pharma. Ranbaxy was up 1.69 per cent at Rs 568.35 whereas Sun Pharma traded 1.06 per cent higher at Rs 769.75.
-
Sell Sun Pharma, Ranbaxy; buy Axis Bank today: Sanjeev Bhasin
For today, long in select auto, banks & infra could make money, while weakness in pharma & steel stocks should do well on the short side.
-
Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover
Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.
-
Ranbaxy's journey as a company to end after merger with Sun Pharma
Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.
-
Sebi to ask stock exchanges for trading data in Ranbaxy shares
Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.
-
Probe Ranbaxy trades ahead of Sun Pharma deal: brokers
Ranbaxy shares surged 24 per cent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy Ranbaxy for $3.2 billion.
-
Sun Pharma soars 8% on upgrades after Ranbaxy deal
Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.
-
Sun Pharma to buy struggling Ranbaxy for $3.2 billion as Daiichi Sankyo retreats
Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co, and got Ranbaxy India-made drugs barred from the United States.
